Evidence map›Paper›PMID 40723053›Full record

ReviewChildren (Basel, Switzerland)2025

False-Positive and False-Negative MRD Results in Children with Acute Lymphoblastic Leukemia: Navigating Between Scylla and Charybdis (Brief Review and Clinical Experience).

Yulia S Korkina, Timur T Valiev, Natalia A Batmanova, Mikhail V Kiselevskiy, Irina Z Shubina, Kirill I Kirgizov, Svetlana R Varfolomeeva

Abstract readReview
In one paragraph

Review in Children (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yulia S KorkinaResearch Institute of Pediatric Oncology and Hematology, FSBI "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of Russia, Kashirskoye Sh.23, Moscow 115522, Russia.
Timur T ValievResearch Institute of Pediatric Oncology and Hematology, FSBI "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of Russia, Kashirskoye Sh.23, Moscow 115522, Russia.ORCID 0000-0002-1469-2365
Natalia A BatmanovaResearch Institute of Pediatric Oncology and Hematology, FSBI "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of Russia, Kashirskoye Sh.23, Moscow 115522, Russia.
Mikhail V KiselevskiyResearch Institute of Experimental Diagnostics and Therapy of Tumors, FSBI "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of Russia, Kashirskoye Sh.24, Moscow 115522, Russia.
Irina Z ShubinaResearch Institute of Experimental Diagnostics and Therapy of Tumors, FSBI "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of Russia, Kashirskoye Sh.24, Moscow 115522, Russia.ORCID 0000-0002-9374-3158
Kirill I KirgizovResearch Institute of Pediatric Oncology and Hematology, FSBI "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of Russia, Kashirskoye Sh.23, Moscow 115522, Russia.
Svetlana R VarfolomeevaResearch Institute of Pediatric Oncology and Hematology, FSBI "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of Russia, Kashirskoye Sh.23, Moscow 115522, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesAcute lymphoblastic leukemia (ALL) is the most common malignant disease in children. Contemporary antitumor treatment protocols provide long-term survival rates in over 90% of patients with ALL. High effectiveness of the treatment has been achieved as a result of chemotherapy optimization, use of targeted drugs, up-to-date genetic information, and detection of minimal residual disease (MRD). Current highly sensitive methods for MRD detection have advantages and disadvantages, and the challenge is to distinguish between false-positive and false-negative tests.

methodsA comprehensive search through MEDLINE, PubMed, Scopus, and ScienceDirect using the MRD-related keywords was performed, and included a final set of 72 academic articles.

resultsAt present, flow cytometry for MRD detection provides the necessary sensitivity of 10

conclusionsThe necessary ground for an adequate sensitivity of the MRD detection methods could ensure the fine line between false-positive and false-negative MRD results in patients with childhood ALL to develop an appropriate therapeutic strategy.

Indexed as

acute lymphoblastic leukemiachildrenfalse-negative MRDfalse-positive MRDflow cytometrygenomic methodsminimal residual disease

Identifiers

PMID40723053
PMCPMC12293285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.